Free Trial

Rallybio (RLYB) Competitors

Rallybio logo
$0.50 -0.02 (-4.39%)
As of 02:20 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

RLYB vs. VTGN, GNTA, RPTX, IRD, ANEB, IKNA, KLTO, CNTX, ASRT, and FBRX

Should you be buying Rallybio stock or one of its competitors? The main competitors of Rallybio include VistaGen Therapeutics (VTGN), Genenta Science (GNTA), Repare Therapeutics (RPTX), Opus Genetics (IRD), Anebulo Pharmaceuticals (ANEB), Ikena Oncology (IKNA), Klotho Neurosciences (KLTO), Context Therapeutics (CNTX), Assertio (ASRT), and Forte Biosciences (FBRX). These companies are all part of the "pharmaceutical products" industry.

Rallybio vs. Its Competitors

VistaGen Therapeutics (NASDAQ:VTGN) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

Rallybio has a net margin of -5,682.19% compared to VistaGen Therapeutics' net margin of -6,777.08%. VistaGen Therapeutics' return on equity of -58.88% beat Rallybio's return on equity.

Company Net Margins Return on Equity Return on Assets
VistaGen Therapeutics-6,777.08% -58.88% -52.38%
Rallybio -5,682.19%-72.31%-64.78%

VistaGen Therapeutics has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. Comparatively, Rallybio has a beta of -1.17, suggesting that its stock price is 217% less volatile than the S&P 500.

Rallybio has a consensus price target of $10.00, indicating a potential upside of 1,896.01%. Given Rallybio's higher probable upside, analysts plainly believe Rallybio is more favorable than VistaGen Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
VistaGen Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Rallybio
0 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

VistaGen Therapeutics has higher earnings, but lower revenue than Rallybio. VistaGen Therapeutics is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VistaGen Therapeutics$486K189.59-$51.42M-$1.66-1.90
Rallybio$640K32.57-$57.78M-$1.09-0.46

In the previous week, VistaGen Therapeutics had 1 more articles in the media than Rallybio. MarketBeat recorded 2 mentions for VistaGen Therapeutics and 1 mentions for Rallybio. Rallybio's average media sentiment score of 1.89 beat VistaGen Therapeutics' score of 0.94 indicating that Rallybio is being referred to more favorably in the news media.

Company Overall Sentiment
VistaGen Therapeutics Positive
Rallybio Very Positive

78.4% of VistaGen Therapeutics shares are owned by institutional investors. Comparatively, 90.3% of Rallybio shares are owned by institutional investors. 1.3% of VistaGen Therapeutics shares are owned by company insiders. Comparatively, 8.7% of Rallybio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

VistaGen Therapeutics and Rallybio tied by winning 8 of the 16 factors compared between the two stocks.

Get Rallybio News Delivered to You Automatically

Sign up to receive the latest news and ratings for RLYB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RLYB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RLYB vs. The Competition

MetricRallybioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$20.85M$3.04B$5.71B$9.51B
Dividend YieldN/A2.40%4.60%3.99%
P/E Ratio-0.4621.1328.0720.02
Price / Sales32.57338.95459.47103.02
Price / CashN/A43.2336.5558.97
Price / Book0.348.278.615.88
Net Income-$57.78M-$55.19M$3.24B$258.50M
7 Day Performance16.51%5.50%3.83%2.03%
1 Month Performance42.94%17.25%10.40%12.52%
1 Year Performance-62.33%4.61%34.13%19.07%

Rallybio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RLYB
Rallybio
2.8947 of 5 stars
$0.50
-4.4%
$10.00
+1,896.0%
-59.7%$20.85M$640K-0.4640Positive News
VTGN
VistaGen Therapeutics
0.4661 of 5 stars
$2.38
flat
N/A-26.4%$69.40M$490K-1.4340News Coverage
GNTA
Genenta Science
2.7286 of 5 stars
$3.78
-4.5%
$25.00
+561.4%
-12.1%$69.14MN/A0.007
RPTX
Repare Therapeutics
2.668 of 5 stars
$1.57
+4.7%
$4.50
+186.6%
-60.1%$67.34M$53.48M-0.52180Positive News
IRD
Opus Genetics
1.6476 of 5 stars
$1.11
-1.8%
$7.33
+560.7%
N/A$66.22M$10.99M-0.5314Gap Up
ANEB
Anebulo Pharmaceuticals
2.0867 of 5 stars
$1.61
-3.0%
$5.50
+241.6%
+35.0%$66.15MN/A-6.194News Coverage
Analyst Forecast
IKNA
Ikena Oncology
2.9779 of 5 stars
$1.37
-0.7%
$3.00
+119.0%
-18.0%$66.11MN/A-1.5970News Coverage
Earnings Report
Analyst Forecast
Gap Up
High Trading Volume
KLTO
Klotho Neurosciences
N/A$1.25
-3.8%
N/AN/A$65.88MN/A-3.47N/A
CNTX
Context Therapeutics
3.3273 of 5 stars
$0.73
+9.3%
$5.50
+651.2%
-62.5%$65.68MN/A-2.367Positive News
ASRT
Assertio
2.3403 of 5 stars
$0.69
-0.8%
$2.75
+301.1%
-50.7%$65.68M$124.96M-2.1420Positive News
FBRX
Forte Biosciences
3.5143 of 5 stars
$9.84
-6.7%
$61.00
+519.9%
+46,966.5%$64.75MN/A-0.605News Coverage
Options Volume

Related Companies and Tools


This page (NASDAQ:RLYB) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners